HER2 expression in renal cell carcinoma is rare and negatively correlated with that in normal renal tissue

Wang,Huili; Liu,Chengyi; Han,Jun; Zhen,Lin; Zhang,Tao; He,Xiaoli; Xu,Enci; Li,Mengqiang

doi:10.3892/ol.2012.727

August 2012 Volume 4 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

August 2012 Volume 4 Issue 2

Full Size Image

Article

HER2 expression in renal cell carcinoma is rare and negatively correlated with that in normal renal tissue

Authors:
- Huili Wang
- Chengyi Liu
- Jun Han
- Lin Zhen
- Tao Zhang
- Xiaoli He
- Enci Xu
- Mengqiang Li
View Affiliations / Copyright

Affiliations: Department of Immunology, Fujian Medical University, Fuzhou, P.R. China, Department of Urology, The Union Hospital of Fujian Medical University, Fuzhou, P.R. China, Department of Pathology, Fujian Medical University, Fuzhou, P.R. China, Institute of Urology, Fujian Medical University, Fuzhou, P.R. China
Pages: 194-198
|
Published online on: May 23, 2012

https://doi.org/10.3892/ol.2012.727
Expand metrics +

Abstract

The aim of this study was to evaluate the status of HER2 protein expression in patients with renal cell carcinoma (RCC) and to determine its prognostic significance. A total of 42 paraffin-embedded tumor tissues and 42 additional corresponding adjacent normal tissues from RCC patients were randomly collected and studied using immunohistochemistry (IHC). Protein samples of 6 fresh specimens from tumor and adjacent normal tissues obtained during surgery were extracted and tested using western blotting to confirm the IHC results. Of the 42 tumor tissues and adjacent normal tissues tested, IHC showed that 7 tumors (16.67%) and 33 adjacent normal tissues (78.57%) expressed the HER2 protein. In addition, results of the western blotting revealed weak HER2 reactivity in primary tumor cells in two of 6 specimens obtained during surgery. All 6 normal tissues showed positive expression, which was in accordance with the outcome of IHC. In conclusion, HER2 is frequently expressed in normal renal tissues and rarely expressed in RCC tissues. Furthermore, the HER2 status of normal tissue is negatively correlated with that of the RCC tissues (r=-0.410, P=0.007) and the TNM stage (r=-0.246, P=0.027), suggesting that HER2 is involved in RCC oncogenesis.

View Figures

View References

1	Fossa SD: Interferon in metastatic renal cell carcinoma. Semin Oncol. 27:187–193. 2000.PubMed/NCBI
2	Klapper LN, Glathe S, Vaisman N, et al: The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA. 96:4995–5000. 1999. View Article : Google Scholar : PubMed/NCBI
3	Reese DM and Slamon DJ: HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells. 15:1–8. 1997. View Article : Google Scholar : PubMed/NCBI
4	Revillion F, Bonneterre J and Peyrat JP: ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer. 34:791–808. 1998. View Article : Google Scholar : PubMed/NCBI
5	Motzer RJ, Bander NH and Nanus DM: Renal-cell carcinoma. N Engl J Med. 335:865–875. 1996. View Article : Google Scholar
6	Disis ML, Wallace DR, Gooley TA, et al: Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol. 27:4685–4692. 2009. View Article : Google Scholar : PubMed/NCBI
7	Tokugawa T, Kobayashi A, Matsuyama T, Imai S and Koyama H: A patient with axillary node metastasis from breast cancer who responded to trastuzumab/capecitabine combination therapy. Gan To Kagaku Ryoho. 36:467–469. 2009.(In Japanese).
8	Zhang XH, Takenaka I, Sato C and Sakamoto H: p53 and HER-2 alterations in renal cell carcinoma. Urology. 50:636–642. 1997. View Article : Google Scholar : PubMed/NCBI
9	Ragab SM, Samaka RM and Shams TM: HER2/neu expression: a predictor for differentiation and survival in children with Wilms tumor. Pathol Oncol Res. 16:61–67. 2010. View Article : Google Scholar : PubMed/NCBI
10	Vasei M, Modjtahedi H, Ale-Booyeh O, et al: Amplification and expression of EGFR and ERBB2 in Wilms tumor. Cancer Genet Cytogenet. 194:88–95. 2009. View Article : Google Scholar : PubMed/NCBI
11	Latif Z, Watters AD, Bartlett JM, Underwood MA and Aitchison M: Gene amplification and overexpression of HER2 in renal cell carcinoma. BJU Int. 89:5–9. 2002. View Article : Google Scholar : PubMed/NCBI
12	Seliger B, Rongcun Y, Atkins D, et al: HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes. Int J Cancer. 87:349–359. 2000. View Article : Google Scholar
13	Laé M, Couturier J, Oudard S, Radvanyi F, Beuzeboc P and Vieillefond A: Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol. 21:815–819. 2010.PubMed/NCBI
14	Shiroiwa T, Fukuda T and Shimozuma K: Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial. Br J Cancer. 105:1273–1278. 2011. View Article : Google Scholar : PubMed/NCBI
15	Srijaipracharoen S, Tangjitgamol S, Tanvanich S, et al: Expression of ER, PR, and Her-2/neu in endometrial cancer: a clinicopathological study. Asian Pac J Cancer Prev. 11:215–220. 2010.PubMed/NCBI
16	Wang H, Wang D, Li M, et al: Enhanced anti-tumor immunity generated by Rituximab-coated tumor cell vaccine. Cancer Lett. 268:129–136. 2008. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

HER2 expression in renal cell carcinoma is rare and negatively correlated with that in normal renal tissue

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles